Eli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended for NHS use in England and Wales as a treatment for atopic dermatitis, also known as eczema.

Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Italy’s Alfasigma SpA in a deal ...

A JAK2 mutation can make your body produce too many blood cells. JAK2 mutations are linked to blood cancers like polycythemia vera and other disorders. Some JAK2 mutations might be linked to Crohn's ...